[A25-73] Rimegepant (prophylaxis of migraine) – Benefit assessment according to §35a Social Code Book V
Last updated 01.09.2025
Project no.:
A25-73
Commission:
Commission awarded on 30.05.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Indication:
Adults with at least 4 migraine attacks per month with an indication for preventive treatment of episodic migraine
Result of dossier assessment:
- Patients for whom conventional migraine prophylaxis is an option: added benefit not proven
- Patients who do not respond to, are unsuitable for, or do not tolerate any of the following drug treatments/drug classes: metoprolol, propranolol, flunarizine, amitriptyline: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-73
| Project no. | Title | Status |
|---|---|---|
| A25-72 | Rimegepant (migraine, acute treatment) – Benefit assessment according to §35a Social Code Book V | Commission completed |